Glycemic and serum lipid control in patients with painful diabetic peripheral neuropathy treated with pregabalin

Aim: To evaluate pregabalin effects on glycemic (hemoglobin Alc [HbAlc] and glucose) and lipid (low- and high-density lipoprotein [LDL and HDL, respectively], and total cholesterol, and triglycerides) control in patients with painful diabetic peripheral neuropathy (pDPN). Methods: Data from 11 randomized, double-blind trials were pooled to assess change-from-baseline treatment differences (pregabalin or placebo) in glycemic and lipid parameters using analysis of covariance. Results: Patients received pregabalin doses (mg/d) of 150 (n = 176), 300 (n = 559), 600 (n = 705), 150-600 (flexible dose, n = 521), or placebo (n = 1050). Statistically significant mean [95% confidence interval] within-treatment (pregabalin) changes occurred in HDL (600 mg/d:-1.61 mg/dl [-3.17,-0.05]), total cholesterol (flexible dose:-6.03 mg/dl [-11.68,-039]), and triglycerides (flexible dose: +15.39 mg/dl [1.56, 29.23]). Statistically significant differences from placebo were found in HbAlc (300 mg/d: +0.11% [0.01, 0.21]) and HDL cholesterol (300 mg/d:-1.78 mg/dl [-336,-0.19], 600 mg/d:-253 mg/dl [-4.49,-057]). No within or between-treatment changes were large enough to be clinically meaningful. Conclusion: No apparent clinically meaningful effects of pregabalin on glycemic/lipid control were found in patients with pDPN. (C) 2017 Published by Elsevier Inc.